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Abstract
Background: It is widely understood that tumor cells express tumor-associated antigens (TAAs), of which many are
usually in low immunogenicity; for example, carcinoembryonic antigen (CEA) is specifically expressed on human
colon cancer cells and is viewed as a low-immunogenic TAA. How to activate host immunity against specific TAAs
and to suppress tumor growth therefore becomes important in cancer therapy development.
Results: To enhance the immune efficiency of CEA in mice that received, we fused a partial CEA gene with
exogenous SARS-CoV fragments. Oral vaccination of an attenuated Salmonella typhimurium strain transformed with
plasmids encoding CEA-SARS-CoV fusion gene into BALB/c mice elicited significant increases in TNF-a and IL-10 in
the serum. In addition, a smaller tumor volume was observed in CT26/CEA-bearing mice who received CEA-SARS-
CoV gene therapy in comparison with those administered CEA alone.
Conclusion: The administration of fusing CEA-SARS-CoV fragments may provide a promising strategy for
strengthening the anti-tumor efficacy against low-immunogenic endogenous tumor antigens.
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Background
Tumor-associated antigens (TAAs) are attractive candi-
dates for cancer therapy in view of their specificity to
tumor targets and safety profile. Although most known
tumor antigens can generate cancer-specific immune
responses, they are either poorly immunogenic or func-
tionally non-immunogenic, and may not elicit immune
responses sufficient to eradicate tumor cells [1]. There-
fore, efforts to enhance TAA-mediated host immunity
towards tumors are being made by exploring a variety
of adjuvants for immunotherapy, adjuvants for cancer
vaccines such as highly-immunogenic vectors, combina-
tions of T-cell co-stimulatory molecules, or immune-sti-
mulatory cytokines usually being employed [2].
Carcinoembryonic antigen (CEA) is a well-known and
over-expressed TAA in most human colon carcinomas,
and vaccination with CEA has been demonstrated to
induce, although with only minor effects, both humoral
and T-cell responses [3]. In order to magnify the CEA-
mediated tumor-specific immune activities, co-adminis-
tration of CEA with other immune-response enhancers
such as granulocyte-macrophage colony-stimulating fac-
tor (GM-CSF) [4] or interleukin (IL)-12 [5] has yielded
promising results with regards to the activation of cellu-
lar and humoral CEA-specific immune responses.
Some antigenic peptides derived from the severe acute
r e s p i r a t o r ys y n d r o m ec o r o n a v i r u s( S A R S - C o V )h a v e
exhibited strong immunogenicity, and specific immuno-
genic epitopes (S978 and S1203) of the S protein of
SARS-CoV have been demonstrated to exhibit a vigor-
ous affinity towards binding with HLA-A2 and induce
high levels of gamma interferon (IFN-g)-secreting T-
cells [6]. Therefore, employment of these highly-immu-
nogenic peptides may boost the positive properties of
CEA tumor vaccines.
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partial sequence of CEA with highly-immunogenic frag-
ments of SARS-CoV, which have been verified consis-
tently to effectively elicit IFN-g secretion in humans [6].
For achieving simple administration of drugs and
enhancement of host immunity, an oral DNA vaccine
vector, Salmonella typhimurium (SL3261) [7], was used
as a carrier to deliver the SARS-CoV-CEA fusion genes.
Using these methods, we sought to demonstrate the
administration of a customized and efficient cancer ther-
apy that combines any selected TAAs and immune-acti-
vating sequences using a simple drug-delivery method.
Significant retardation of tumor growth and increased
survival were observed in mice with cancers in our
study, and the results obtained using this strategy were
therefore promising.
Results
Prediction of H2-Kd binding epitopes from CEA-SRAS-CoV
fusion polypeptides
The SYFPEITHI prediction algorithm was used to pre-
dict peptide/H2-Kd interaction by affinity calculation.
To find a low-immunogenicT A Aa n dp r e v e n tt h e
human TAA from activating mouse immunity, a trun-
cated CEA peptide was used as a low-immunogenic
tumor antigen in this study, the sequence of which is
shown in Figure 1a. The CEA sequence was predicted
to be less immunogenic by affinity calculation because
its highest epitope score (CEA a.a. No. 5-13 (Figure 1a):
epitope score 16) was far lower than the scores of well-
known epitopes of Listeria monocytogenes (Listeriolysin
O) (LLO91-99: epitope score 24; p60217-225: epitope
score 27) (Table 1). A selected SARS fragment was
fused with CEA, and this sequence is shown in Figure
1b. As described previously, the epitope within the
CEA-SARS-CoV amino acid sequence was also calcu-
lated and compared with known epitopes in Listeria
monocytogenes (LLO91-99, p60217-225). As a result, the
highest score within the CEA-SARS sequence was 21 in
the SARS region (Table 2), lower than the scores of
known epitopes of L. monocytogenes for peptide/H2-Kd
interaction. In addition, fusion of the CEA and SARS
sequences did not create a new epitope with a higher
score (data not shown).
Effects of tumor vaccines on cytokine profiles
To examine the cytokine profiles of the different immu-
nized groups quantitatively, sera samples were collected
from each group 4 weeks after vaccination (i.e., 2 weeks
after tumor inoculation), and cytokines representing
Th1 (TNF-a,) and Th2 (IL-10) were detected by ELISA.
The pCEA-SARS-CoV group revealed significantly
higher TNF-a and IL-10 production than the pCEA and
control groups (p < 0.05) (Figure 2)
Vaccination and therapeutic effects of orally-administered
pCEA- and pCEA-SARS-CoV-transformed S. typhimurium
To determine the efficacy of the pCEA-SARS-CoV tumor
vaccine, mice were orally immunized with 1 × 10
8 pCEA-
and pCEA-SARS-CoV-transformed S. typhimurium 14
Figure 1 Flanking nucleotide sequences of the CEA and SARS epitopes. (a) 132 bps (nucleotides 12804~10935) of the CEA sequence (NCBI
accession No. Z21818) and (b) 177 bps of the SARS sequence (NCBI accession No. AB263618) were used as the starting materials to generate
highly-immunogenic mutations. The grey area indicates the epitope used for affinity prediction.
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cells. As per the data shown in Figure 3, the tumor
volume was significantly lower in the pCEA-SARS-CoV
group (p < 0.05) as compared with the pCEA group, indi-
cating that the SARS fragment provided sufficient protec-
tion against the development of tumors.
Regarding the therapeutic effects of the vaccines, mice
were inoculated with 1 × 10
5 CT26/CEA and 4 days later
orally immunized with 1 × 10
8 S. typhimurium trans-
formed with pCEA, or pCEA-SARS-CoV in 20 μlP B S ,
while the negative control group was fed with 20 μlP B S .
While therapy with pCEA was not able to induce
responses to reduce the growth of tumors in comparison
with the control group, mice in the CEA-SARS-CoV
group exhibited significantly less tumor growth, indicat-
ing that the SARS fragment provided adequate protection
against CT26/CEA (Figure 4, p < 0.05 in comparison with
the control and the pCEA group).
Discussion
Our results demonstrated that fusion peptides composed
of a highly-immunogenic epitope and a poorly-immu-
noreactive tumor-associated antigen can effectively acti-
vate host immunity, and furthermore, using the
prediction algorithm SYFPEITHI to enhance the affinity
of antigen presentation, the resulting fusion peptides
provoked even stronger immune responses. In addition,
this study also provided new insight into tumor-specific
Table 1 Comparison of the CEA and CEA-SARS epitopes with other known epitopes that have been proven to elicit
immunity in BALB/c mice.
Gene Primer Sequence (5’®3’) Tm (°C)
P1 TACggAATTCATggAgTCTCCCTCggCCCCTCCCCACAgATggTgCATCC 71.6
P2 CCTggCAgAggCTCCTgCTCACAggTgAAgggAggACAAC 71.5
P3 CTgggAgAgggTgggAGggAgggAgCTggggTCTCCTgggT 75.1
CEA P4 CTCCTCCCACCCTCTCCCAggTTgTCCTCCCTTCACCTgT 71.8
P5 gAgCAggAgCCTCTgCCAggggATgCACCATCTgTggggA 73.7
P6 gCTATC TAgATCACAgCCCTgTCCTACCCAggAgACCCCAgCTCC 71.1
P7 gCTATCTAgACAgCCCTgTCCTACCCAggAgACCCCAgCTCC 71.0
P1 TACgTCTAgAAAAgTCgAggCggAggTACAAATTgACAggTTAATTACA 65.7
P2 ggCAgACTTCAAAgCCTTCAAACCTATgTAACACAACAAC 63.9
P3 TAATCAggATTAAATggCCTTggTATgTTTggCTCggCTT 65.3
SARS P4 CATTgCTggACTAATTgCCATCgTCATggTTACAATCTTg 63.7
P5 gCTAAAgCTTTTAAgTCATgCAACAAAgCAAgATTgTAACCATgACgA 64.1
P6 TggCAATAgTCCAgCAATgAAgCCgAgCCAAACATACCA 67.7
P7 AggCCATTTAATCCTgATTAgTTgTTgTgTTACATggTT 61.7
P8 TgAAggCTTTgAAgTCTgCCTgTAATTAACCTGgTCAATTT 63.2
Table 2 PCR primers used to synthesize CEA and SARS
peptides.
H2-Kd nonamer Amino acid Score References
CEA SAPPHRWCI 16 NCBI accession No. Z21218
SARS WYVWLGFIA 21 NCBI accession No. AB263618
Listeria LLO91-99 GYKDGNEYI 24 Nakamura et al., 2003
Listeria p60217-225 KYGVSVQDI 27 Bouwer et al., 1996
EGFP200-208 HYLSTQSAL 27 Gambotto et al., 2001
Predicted by the SYFPEITHI algorithm.
Figure 2 Serum cytokine profiles of BALB/c mice orally-
vaccinated with CEA-SARS-derived epitopes. Sera samples were
collected for in vivo cytokine detection, including (a) TNF-a and (b)
IL-10. (*, p < 0.05 in comparison with the control and the pCEA
group).
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unrelated antigenic fragment, with CEA, we finally
demonstrated this could be a promising anti-cancer
strategy through effectively increasing both Th1 and
Th2 cytokines and decreasing tumor volume.
The DNA vaccine, though usually injected intramus-
cularly, can be administered orally in an animal model
with bacteria, and it has been observed that some dis-
play preferential replication or preferential accumulation
in the tumor microenvironment [8]. Among all bacteria,
S. typhimurium is one of the most utilized to carry ther-
apeutic transgenes. Attenuation of S. typhimurium with
partial gene modifications does not affect its ability to
achieve high tumor/normal tissue ratios in mouse mod-
els, and the bacteria maintain their capacity to inhibit
the growth of both subcutaneous tumors and lung
metastatic diseases [8]. Other modifications have also
been reported; for example, the strain used in this study
was attenuated aromatic acid-dependent (aro) S. typhi-
murium, which has been well-characterized as a carrier
of various heterogeneous antigens [9,10]. These vaccine
strains are capable of colonizing the gut-associated lym-
phoid tissues (Peyer’s patches) and secondary lymphatic
tissues including the spleen and liver following oral
administration in mice, eliciting mucosal, humoral and
cell-mediated immune responses [11]. Previous studies
have proven the lipopolysaccharides on the Salmonella
s u r f a c ee n a b l eC D 1 4 +m o n o c y t e st os e c r e t eT N F - a,I L -
1 and IL-6 [12,13]. Also S. Typhimurium could deliver
directly into the cytosol of macrophages and dendritic
Figure 3 In vivo tumor development of BALB/c mice after oral vaccination. Five BALB/c mice in each treatment group were inoculated
with CT26/CEA cells 21 days after vaccination with pCEA- and pCEA-SARS-transformed S. typhimurium and the tumor volume in the mice was
observed. (*, p < 0.05 in comparison with the control and the pCEA group).
Figure 4 Therapeutic effect of CEA-SARS-derived epitopes on
tumor establishment. BALB/c mice were inoculated with CT26/
CEA cells on day 0. Four days later, the mice were fed with pCEA-
and pCEA-SARS-transformed S. typhimurium once per week (5 mice/
group), and the subsequent tumor volume in the mice was
observed. (*, p < 0.05 in comparison with the control and the pCEA
group).
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priming and the induction of protective immunity
against viruses, bacteria and tumors [14,15].
Variations in the cytokine profiles arose after vaccination
with pCEA-SARS-CoV. As a highly-immunogenic peptide,
treatment with SARS-containing epitopes has elicited a
striking increase in TNF-a expression as compared with
the negative control and the CEA group (Figure 2a). TNF-
a is a proinflammatory and Th1 cytokine, and as indicated
by Austin and colleagues, TNF-a, IFN-g, and IL-2 can be
used to define cytotoxic T lymphocytes and Th1 effector
populations [16]. Reducing local expression of TNF-a was
found to be associated with B16-F10 melanoma outgrowth
in mice while s.c. administrating TNF-a significantly sup-
pressed primary tumor growth of melanoma [17]. IL-10, a
typical Th2 cytokine, was enhanced in the pCEA-SARS-
CoV group as compared with the negative control and the
CEA group (Figure 2b). Though most often known as a
Th2 cytokine, IL-10 is actually a pleiotropic cytokine with
anti-inflammatory, immunosuppressive, and immunosti-
mulatory properties [18], and exerts immunostimulatory
effects on B cells, cytotoxic T-cell development and thy-
mocytes [19]. As indicated by Wogensen et al., expression
of an IL-10 transgene by insulin-producing pancreatic
cells led to the accelerated onset of diabetes in NOD mice
[20,21], with no inhibition of immune-mediated destruc-
tion of islets [22].
In the study of Moritani et al., NOD (Non-obese dia-
betic) mice expressing an IL-10 transgene in glucagon-
producing pancreatic cells also developed accelerated
diabetes [23]. Consequently, the expression of IL-10 in
our model may exert not only a Th2 effect but also a
Th1 effect. In general, the CEA antigen only induces a
Th2 response, whereas the addition of a SARS fragment
helps to induce and enhance both Th1 and Th2
responses. Th1 is more famous for its antitumor effects,
although Th2 responses have been reported in autolo-
gous tumors, T-cells from patients with indolent non-
Hodgkin lymphomas frequently exhibiting an activated
but apoptosis-prone phenotype [24]. It may seem that
the Th2 response might downregulate the effect of a
Th1 response or contribute less to the antitumor activ-
ity, but Th2-dominated antitumor immunity has also
been observed in some models. As reported by Chu et
al. [25], their DNA vaccine, which comprised a modified
core peptide of mucin1 (PDTRP) and a GM-CSF coding
sequence at the C-terminus, induced better protection
against tumor challenge, and that protection was corre-
lated with type 2 immune responses manifested by an
increased IgG1 to IgG2a antibody ratio and greater
i n d u c t i o no fG A T A - 3a n dI L - 4m R N At h a no fT - b e t
and IFN-g mRNA in spleen cells of vaccinated mice.
The enhancement of Th1 and Th2 in the SARS-frag-
ment-containing treatment groups indeed displayed
better immunoactivity and protective effects in CT26/
pCEA-bearing mice. In comparison with the negative
control group, no significant differences in tumor
volume were observed in mice immunized with CEA
alone, while the tumor volume was found to be smaller
in the pCEA-SARS-CoV group in the protection and
therapy assays (Figure 3 &4). These results may indicate
that enhancement of the affinity of antigen presentation
by the prediction algorithm increased the immunogeni-
city of the CEA-SARS peptide.
Conclusions
This study has demonstrated a potential strategy to
overcome traditional obstacles in TAA-specific tumor
therapy, and has shown that it is possible for foreign
SARS fragments to improve the anti-tumor efficacy of
tumor vaccines against endogenous tumor antigens.
Application of these kinds of highly-immunogenic pep-
tides and the enhancement of peptide affinity through
prediction software could serve as a platform to elicit
powerful host immunity and eliminate tumor growth.
Methods
Cell culture
All cell lines were obtained from the American Type
Culture Collection (VA, USA). CT26 (mouse colon cell,
ATCC: CRL-2638), PT67 (mouse retrovirus-packaging
cell line, ATCC: CRL-12284), and BALB/3T3 (mouse
embryo fibroblast, ATCC: CCL-163.2) were cultured in
RPMI media supplemented with 2 mM L-glutamine, 50
μg/ml of Penicillin/Streptomycin (P/S) and 10% heat-
inactivated fetal bovine serum (FBS) (Biological Indus-
tries, Haemek, Israel) at 37°C under 5% CO2. CT26/
CEA cells were generated by transfecting retroviral vec-
tors (pMSCV neo) carrying CEA DNA fragments (NCBI
accession No. Z21818, nucleotide (nt.) CEA10804~10938,
132 bp). CT-26 transfectant cells (CT26/CEA) were
obtained by G418 (Protech, Taiwan) selection and main-
tained in the RPMI growth medium described above.
Prediction of H2-Kd-immunogenic amino-acid peptides
A fragment derived from the SARS coronavirus (SARS-
CoV) (NCBI accession No. AB263618) that has proved
to be effective in eliciting IFN-g secretion in humans [6]
was selected for use in this study and fused with CEA, a
low-immunogenic peptide for peptide-binding predic-
tion. The SYFPEITHI scoring system [26] was then uti-
lized to predict the affinity of CEA and CEA-SARS-CoV
peptides towards binding to BALB/c H2-Kd molecules.
Construction of vectors for CEA and CEA-SARS-CoV gene
expression
The eukaryotic expression plasmid pAAV-MCS was
chosen for gene insertion and expression under the
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CEA and SARS-CoV were both artificially synthesized
by polymerase chain reaction (PCR) using a series of
sense and antisense primers designed precisely accord-
ing to the above two gene sequences (Table 1), which
provided suitable restriction enzyme sites. Because the
antisense sequences overlapped with the sense
sequences for 20 bps in the designed primers, they will
base-pair with each other. The CEA fragment with the
restriction enzyme sites EcoRI 5’ and XbaI 3’ and
pAAV-MCS were both digested with EcoRI and XbaI
and then ligated to form pCEA. The SARS fragment
with XbaI 5’ and HindIII 3’ and pCEA were both
digested with XbaI and HindIII and then ligated to form
pCEA-SARS-CoV.
Oral infection of BALB/c mice with Salmonella
Plasmids were electroporated into the Salmonella vaccine
vector (S. typhimurium strain SL3261) at 2.5 mF, 2.5 kV,
and 200Ω for 4~5 msec, and quantification of the bac-
teria was performed by plating serial dilutions in LB
plates. Six-eight-week-old female BALB/c mice were pur-
chased from the National Laboratory Center (Taipei, Tai-
wan) and housed in a temperature- and light-controlled
(12L:12D) environment at the Animal Maintenance Facil-
ity of National Chiao Tung University (NCTU)
(HsinChu, Taiwan). The institutional animal care and use
committee of NCTU approved this study before its start.
Mice in the treatment groups were immunized with 1 ×
10
8 attenuated S. typhimurium (in 20 μlP B S )t r a n s -
formed with the different vectors (pCEA and pCEA-
SARS-CoV) three times in two weeks, while the negative
control group was fed with 20 μl PBS alone.
ELISA
To evaluate the cytokine profiles of the mice after
immunization with pCEA- and pCEA-SARS-CoV-trans-
formed S. typhimurium, sera samples were collected at
day 14 and assayed for TNF-a and IL-10 expression by
standard ELISA (R&D, MN, USA) in compliance with
the manufacturer’s instructions.
Vaccine protection assay
For the vaccine protection assay, 6-8-week-old BALB/c
mice were immunized using the protocol described in
the previous section. One week after the last booster
injection, mice were inoculated with 5 × 10
5 CT26/CEA
cells and the tumor growth pattern was measured every
4 days. Tumor volume was calculated using the formula
volume = length × width × height.
Vaccine therapeutic assay
To evaluate the tumor therapy, BALB/c mice were
inoculated with 1 × 10
5 CT26/CEA cells (in 200 μl PBS/
mouse) and orally immunized with 1 × 10
8 S. typhimur-
ium (in 20 μl PBS/mouse) 4 days later, followed by re-
immunization once a week after the first injection.
Statistical analysis
Results are expressed as mean ± SE. Student’s t test was
applied to compare the effects of treatment in the differ-
ent groups, and the Mantel-Cox significance test was
employed to analyze the survival rate. A value of p <
0.05 was considered significant.
Author details
1School of Veterinary Medicine, National Taiwan University, Taipei, Taiwan.
2Department of Biological Science and Technology, National Chiao-Tung
University, Hsin-Chu, Taiwan.
3Department of Food Science, National Taiwan
Ocean University, Keelung, Taiwan.
4Department of Nursing, Tzu Chi
University, Hualien, Taiwan.
Authors’ contributions
KWL and CSL conceived the study aims and design, contributed to the
systematic review and data extraction, performed the analysis and
interpreted the results. SHK drafted the manuscript and performed the
experiments. YCC, CHL, YTH, and SCY assisted in doing experiments. CJW
and RPL contributed to the revision of the manuscript. All authors have read
and approved the final version of this paper.
Competing interests
We (authors in this manuscript) declares that we have no significant
competing financial, professional or personal interests that might have
influenced the performance or presentation of the work described in this
manuscript.
Received: 14 November 2011 Accepted: 3 February 2012
Published: 3 February 2012
References
1. Reuschenbach M, von Knebel Doeberitz M, Wentzensen N: A systematic
review of humoral immune responses against tumor antigens. Cancer
Immunol Immunother 2009, 58:1535-1544.
2. Hodge JW, Greiner JW, Tsang KY, Sabzevari H, Kudo-Saito C,
Grosenbach DW, Gulley JL, Arlen PM, Marshall JL, Panicali D, Schlom J:
Costimulatory molecules as adjuvants for immunotherapy. Front Biosci
2006, 11:788-803.
3. Hallermalm K, Johansson S, Brave A, Ek M, Engstrom G, Boberg A,
Gudmundsdotter L, Blomberg P, Mellstedt H, Stout R, et al: Pre-clinical
evaluation of a CEA DNA prime/protein boost vaccination strategy
against colorectal cancer. Scand J Immunol 2007, 66:43-51.
4. Dai S, Wei D, Wu Z, Zhou X, Wei X, Huang H, Li G: Phase I clinical trial of
autologous ascites-derived exosomes combined with GM-CSF for
colorectal cancer. Mol Ther 2008, 16:782-790.
5. Ojima T, Iwahashi M, Nakamura M, Matsuda K, Nakamori M, Ueda K, Naka T,
Ishida K, Primus FJ, Yamaue H: Successful cancer vaccine therapy for
carcinoembryonic antigen (CEA)-expressing colon cancer using
genetically modified dendritic cells that express CEA and T helper-type
1 cytokines in CEA transgenic mice. Int J Cancer 2007, 120:585-593.
6. Wang YD, Sin WY, Xu GB, Yang HH, Wong TY, Pang XW, He XY, Zhang HG,
Ng JN, Cheng CS, et al: T-cell epitopes in severe acute respiratory
syndrome (SARS) coronavirus spike protein elicit a specific T-cell
immune response in patients who recover from SARS. J Virol 2004,
78:5612-5618.
7. Darji A, Guzman CA, Gerstel B, Wachholz P, Timmis KN, Wehland J,
Chakraborty T, Weiss S: Oral somatic transgene vaccination using
attenuated S. typhimurium. Cell 1997, 91:765-775.
8. Sznol M, Lin SL, Bermudes D, Zheng LM, King I: Use of preferentially
replicating bacteria for the treatment of cancer. J Clin Invest 2000,
105:1027-1030.
Lin et al. Biological Procedures Online 2012, 14:2
http://www.biologicalproceduresonline.com/content/14/1/2
Page 6 of 79. Dougan G, Hormaeche CE, Maskell DJ: Live oral Salmonella vaccines:
potential use of attenuated strains as carriers of heterologous antigens
to the immune system. Parasite Immunol 1987, 9:151-160.
10. Fagan PK, Djordjevic SP, Chin J, Eamens GJ, Walker MJ: Oral immunization
of mice with attenuated Salmonella typhimurium aroA expressing a
recombinant Mycoplasma hyopneumoniae antigen (NrdF). Infect Immun
1997, 65:2502-2507.
11. Molecular and Clinical Aspects of Bacterial Vaccine Development. Edited
by: Hormaeche DAAAACE 1995.
12. Proskuryakov SY, Gabai VL: Mechanisms of tumor cell necrosis. Curr Pharm
Des 2010, 16:56-68.
13. Wright SD, Ramos RA, Patel M, Miller DS: Septin: a factor in plasma that
opsonizes lipopolysaccharide-bearing particles for recognition by CD14
on phagocytes. J Exp Med 1992, 176:719-727.
14. Russmann H, Shams H, Poblete F, Fu Y, Galan JE, Donis RO: Delivery of
epitopes by the Salmonella type III secretion system for vaccine
development. Science 1998, 281:565-568.
15. Walker EB, Disis ML: Monitoring immune responses in cancer patients
receiving tumor vaccines. Int Rev Immunol 2003, 22:283-319.
16. Austin LM, Ozawa M, Kikuchi T, Walters IB, Krueger JG: The majority of
epidermal T cells in Psoriasis vulgaris lesions can produce type 1
cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-
alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector
populations: a type 1 differentiation bias is also measured in circulating
blood T cells in psoriatic patients. J Invest Dermatol 1999, 113:752-759.
17. Nakasone YFM, Matsushita T, Hamaguchi Y, Huu DL, Yanaba M, Sato S,
Takehara K, Hasegawa M: Host-Derived MCP-1 and MIP-1α Regulate
Protective Anti-Tumor Immunity to Localized and Metastatic B16
Melanoma. The American journal of pathology 2011.
18. Moore KW, de Waal Malefyt R, Coffman RL, O’Garra A: Interleukin-10 and
the interleukin-10 receptor. Annu Rev Immunol 2001, 19:683-765.
19. Conti P, Kempuraj D, Kandere K, Di Gioacchino M, Barbacane RC,
Castellani ML, Felaco M, Boucher W, Letourneau R, Theoharides TC: IL-10,
an inflammatory/inhibitory cytokine, but not always. Immunol Lett 2003,
86:123-129.
20. Wogensen L, Huang X, Sarvetnick N: Leukocyte extravasation into the
pancreatic tissue in transgenic mice expressing interleukin 10 in the
islets of Langerhans. J Exp Med 1993, 178:175-185.
21. Wogensen L, Lee MS, Sarvetnick N: Production of interleukin 10 by islet
cells accelerates immune-mediated destruction of beta cells in
nonobese diabetic mice. J Exp Med 1994, 179:1379-1384.
22. Lee MS, Wogensen L, Shizuru J, Oldstone MB, Sarvetnick N: Pancreatic islet
production of murine interleukin-10 does not inhibit immune-mediated
tissue destruction. J Clin Invest 1994, 93:1332-1338.
23. Moritani M, Yoshimoto K, Tashiro F, Hashimoto C, Miyazaki J, Ii S, Kudo E,
Iwahana H, Hayashi Y, Sano T, et al: Transgenic expression of IL-10 in
pancreatic islet A cells accelerates autoimmune insulitis and diabetes in
non-obese diabetic mice. Int Immunol 1994, 6:1927-1936.
24. Anichini A, Mortarini R, Romagnoli L, Baldassari P, Cabras A, Carlo-Stella C,
Gianni AM, Di Nicola M: Skewed T-cell differentiation in patients with
indolent non-Hodgkin lymphoma reversed by ex vivo T-cell culture with
gammac cytokines. Blood 2006, 107:602-609.
25. Chu Y, Xia M, Lin Y, Li A, Wang Y, Liu R, Xiong S: Th2-dominated
antitumor immunity induced by DNA immunization with the genes
coding for a basal core peptide PDTRP and GM-CSF. Cancer Gene Ther
2006, 13:510-519.
26. Rammensee HG, Friede T, Stevanoviic S: MHC ligands and peptide motifs:
first listing. Immunogenetics 1995, 41:178-228.
doi:10.1186/1480-9222-14-2
Cite this article as: Lin et al.: Enhancement of anti-murine colon cancer
immunity by fusion of a SARS fragment to a low-immunogenic
carcinoembryonic antigen. Biological Procedures Online 2012 14:2.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Lin et al. Biological Procedures Online 2012, 14:2
http://www.biologicalproceduresonline.com/content/14/1/2
Page 7 of 7